Atrial fibrillation (AF) is an important risk factor for ischemic stroke resulting in a fivefold
increased stroke risk and a twofold increased mortality. Our understanding of stroke …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Introduction: The real-world treatment of atrial fibrillation (AF) often involves the prescription
of new oral anticoagulants (NOACs) using dosing both lower and higher than recommended …

Objectives To examine variation in outcomes, outcome measurement instruments (OMIs)
and measurement times in clinical trials of non-valvular atrial fibrillation (NVAF) and to …

The standard of care for oral anticoagulation therapy has primarily been warfarin, which is
limited by its indirect mechanism-of-action, variable kinetics, tolerability, and routine …

The aetiology of ischemic vascular stroke (IVS) is various, the most common cause being
cardioembolic, and anticoagulation treatment plays an essential role in the prevention of …

Introduction In the pivotal RE-LY trial, dabigatran etexilate (DE) at the dose of 150-mg twice
daily (BID), significantly reduced total stroke and ischemic stroke compared with warfarin in …

背景心房颤动是临床上最常见的心律失常之一, 血栓形成是心房颤动的常见并发症.
长期以来华法林作为心房颤动患者抗凝的首选药物, 其不良反应一直困扰着临床医生和患者 …

Objectives Dabigatran has a better safety profile and requires less monitoring, but is costlier
than warfarin. This study evaluated the cost-utility of dabigatran relative to warfarin for …